BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023
BrainsWay Ltd. (NASDAQ: BWAY) announced plans to report its Q4 and full-year 2022 financial results on March 15, 2023, prior to U.S. market opening. The company will host a conference call at 8:30 AM ET to discuss these results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its Deep TMS technology, which has received FDA clearance for multiple indications including major depressive disorder and obsessive-compulsive disorder. This announcement aims to inform stakeholders and enhance transparency regarding its operational performance.
- None.
- None.
BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its fourth quarter and full year 2022 financial results as well as operational highlights before the open of the U.S. financial markets on Wednesday, March 15, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, March 15, 2023 |
| Time: | 8:30 AM Eastern Time |
| United States: | 877-407-3982 |
| International: | 201-493-6780 |
| Conference ID: | 13736480 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1599119&tp_key=702da0691e |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
Contacts:
BrainsWay:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
Scott.Areglado@brainsway.com
Investors:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com
FAQ
When will BrainsWay report its financial results for Q4 2022?
What time is the BrainsWay conference call scheduled for?
How can I access the BrainsWay conference call?
What is BrainsWay's primary technology for mental health treatment?
What indications has BrainsWay's technology received FDA clearance for?
